ESTRO 2022 - Abstract Book

S1604

Abstract book

ESTRO 2022

exceeded with treatment by the same plan. Thus, CT guided brachytherapy must be implemented for every fr treatment in carcinoma cervix.

PO-1799 Cervical cancer treated whit HDR-brachytherapy MRI-based according to the recommendations GEC-ESTRO

M.F. Ropero Carmona 1 , J. Quirós Rivero 2 , J.L. Muñoz García 2 , J.J. Cabrera Rodríguez 2 , Y. Ríos Kavadoy 2 , V. Vera Barragán 2 , P. Simón Silva 2 , B. Baños Pérez 2 , C. Corral Fernandez 2 , M. Gonzalez de Dueñas 2 1 Complejo Hospitalario de Badajoz , Oncología Radioterápica, Badajoz, Spain; 2 Complejo Hospitalario Universitario Badajoz, Oncología Radioterápica, Badajoz, Spain Purpose or Objective To report our experience in patients with cervical cancer treated with External Beam Radiotherapy (EBRT) and High-Dose- Rate Intracavitary Brachytherapy (HDR-BT) MRI based IGABT (Image Guided Adaptive Brachytherapy). The standard treatment for locally advanced cervical cancer is currently radio-chemotherapy consisting of EBRT plus concomitant chemotherapy with Cisplatin weekly and intracavitary BT. GEC ESTRO recommends the use image-based brachytherapy and Retro-EMBRACE and EMBRACE, which will establish MRI- guided brachytherapy as a gold standard. Materials and Methods From October 2015 to October 2020, 60 patients with cervical cancer stages I-IV underwent definitive treatment. Patients were subjected to MRI-based-Brachytherapy post EBRT/concurrent chemotherapy using GEC-ESTRO guidelines. Median age was 56 years. Histology was 73% squamous cell carcinoma and 27% adenocarcinoma. The most frequent clinical stage was IIB (54%). The median tumor size was 45 mm. Median dose EQD2 total ( α / β =10) was 89Gy. Median dose HR- CVTD90 ( α / β =10) 90Gy and IR-CVTD90 67Gy. The median dose of organs at risk (OAR) D2cc EQD2 ( α / β =3): bladder 73Gy, rectum 64Gy and sigma 62Gy. The overall treatment time was ≥ 8 weeks in 98.2% of the patients with a median overall treatment time of 78 days. Toxicity was evaluated by CTCAE v4.0. Local Control (LC), Disease Free Survival. (DFS) and Overall Survival (OS) were estimated using the Kaplan-Meier method. Results With a median follow-up of 42 months (8-68), LC was 95%. MRI-confirmed complete response was 82%. The first relapse was Local recurrence 4%, Pelvic recurrence 2%, Local and regional recurrence 2% and distant metastasis 18%. The 4-year LC, DFS and OS rates were 96%, 72.5% and 82%, respectively. Prevalence rates of acute toxicity intestinal were G1 18%; rectal acute toxicity was 25% G1, 2% G3 (1 patient) and bladder acute toxicity was G1 11%. We have not observed G3 toxicity intestinal or bladder. Prevalence rates of chronic toxicity intestinal were G2 4%, bladder chronic toxicity G1 4%, G3 2% and rectal chronic toxicity G1 4% and G3 4% (2 patients). Conclusion HDR-BT MRI based IGABT allows doses >90Gy to HDR-CTV to be administered getting a good LC whit acceptable toxicity. We need to improve the overall treatment time. 1 national Institute Of Oncology, Ibn Sina Teaching Hospital, Mohamed V Souissi University, Radiation Oncology Department, Rabat, Morocco Purpose or Objective Brachytherapy is an invasive procedure that can cause a wide range of physical and emotional difficulties; however, very little data exists on this subject in the literature. The aim of this study was to establish cervical cancer patients’ expectations, experiences, informational needs and understandings of the high dose-rate (HDR) intracavitary brachytherapy procedure, as part of a process to develop guidelines for quality patient-centered care. Materials and Methods A prospective, qualitative study with a descriptive phenomenological approach was used. Purposive sampling was carried out to recruit 31 women undergoing HDR brachytherapy for cervical cancer from June to August 2020 at the National Institute of Oncology in Rabat. Semi-structured, one-to-one interviews guided by a theme list were conducted by a female radiation oncologist in Arabic before, during and after treatment. The following aspects were discussed: treatment information given and understood, expectations, experiences in the waiting room, in the treatment room, and suggestions for improvement. Data was transcribed, translated and thematic analysis performed. PO-1800 Experiences of women receiving brachytherapy for cervical cancer: a prospective qualitative study. K. Benali 1 , H. Benmessaoud 1 , H. Ahmut 1 , S. Elmajjaoui 1 , T. Kebdani 1 , H. El Kacemi 1 , K. Hassouni 1 , N. Benjaafar 1